stoxline Quote Chart Rank Option Currency Glossary
  
COMPASS Pathways plc (CMPS)
6.9  -0.27 (-3.77%)    01-26 16:00
Open: 7.0928
High: 7.1
Volume: 1,488,743
  
Pre. Close: 7.17
Low: 6.55
Market Cap: 662(M)
Technical analysis
2026-01-26 4:39:51 PM
Short term     
Mid term     
Targets 6-month :  8.65 1-year :  9.57
Resists First :  7.41 Second :  8.19
Pivot price 7.22
Supports First :  6.13 Second :  5.1
MAs MA(5) :  7.1 MA(20) :  7.1
MA(100) :  6.09 MA(250) :  4.78
MACD MACD :  0.1 Signal :  0.2
%K %D K(14,3) :  41.2 D(3) :  43.2
RSI RSI(14): 49.5
52-week High :  8.19 Low :  2.25
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CMPS ] has closed above bottom band by 23.2%. Bollinger Bands are 10.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 7.15 - 7.19 7.19 - 7.23
Low: 6.46 - 6.5 6.5 - 6.54
Close: 6.84 - 6.91 6.91 - 6.97
Company Description

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Headline News

Mon, 26 Jan 2026
COMPASS Pathways (NASDAQ:CMPS) Stock Price Down 7.6% - Should You Sell? - MarketBeat

Fri, 23 Jan 2026
COMPASS Pathways Target of Unusually High Options Trading (NASDAQ:CMPS) - MarketBeat

Fri, 23 Jan 2026
COMPASS Pathways Plc (CMPS) Stock Analysis: Exploring a 135.88% Potential Upside in Mental Health Innovation - DirectorsTalk Interviews

Thu, 22 Jan 2026
Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds - Psychedelic Alpha

Thu, 22 Jan 2026
COMPASS Pathways’ key patents upheld by the US Patent and Trademark Office - Psychedelic Alpha

Mon, 12 Jan 2026
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression and Clinical Trial Plans for Post-Traumatic Stress Disorder on January 7, 2026, 10:00am ET - Investing News Network

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Care Facilities
Shares Out 96 (M)
Shares Float 68 (M)
Held by Insiders 12.1 (%)
Held by Institutions 62.2 (%)
Shares Short 4,960 (K)
Shares Short P.Month 6,240 (K)
Stock Financials
EPS -2.73
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.38
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -38.5 %
Return on Equity (ttm) -205.9 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.61
Qtrly Earnings Growth 0 %
Operating Cash Flow -161 (M)
Levered Free Cash Flow 47 (M)
Stock Valuations
PE Ratio -2.54
PEG Ratio 0
Price to Book value 17.69
Price to Sales 0
Price to Cash Flow -4.11
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android